CTY press release

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the closing of its upsized initial public offering of 12,777,777 shares of its common stock at a public offering price of $18.00 per share, which includes 1,666,666 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to City from the offering, including full exercise of the underwriters’ option to purchase additional shares, were approximately $230.0 million, before deducting underwriting discounts and commissions and offering expenses payable by City. All of the shares of common stock were offered by City.

City’s common stock began trading on the Nasdaq Global Market on October 16, 2026, under the ticker symbol “CTY.”